Cannabidiol efficacious for lennox-gastaut drop seizures

January 26, 2018

(HealthDay)—For patients with drop seizures associated with Lennox-Gastaut syndrome, add-on cannabidiol is associated with a reduction in monthly drop seizure frequency, according to a study published online Jan. 24 in The Lancet.

Elizabeth A. Thiele, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a randomized trial at 24 clinical sites to examine the efficacy of cannabidiol as add-on therapy for drop seizures in 171 patients with treatment-resistant Lennox-Gastaut syndrome. Participants were randomized in a 1:1 ratio to cannabidiol (86 patients) or placebo (85 patients).

The researchers found that the median percentage reduction in monthly drop seizure frequency was 43.9 and 21.8 percent in the cannabidiol and placebo groups, respectively. During the 14-week treatment period, the estimated median difference between treatment groups was −17.21. Adverse events occurred in 86 and 69 percent of patients in the cannabidiol and placebo groups, respectively; most were mild or moderate. Diarrhea, somnolence, pyrexia, decreased appetite, and vomiting were the most common adverse effects. Due to , 12 patients in the cannabidiol group and one in the withdrew from the study.

"Add-on cannabidiol is efficacious for the treatment of with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated," the authors write. "The long-term efficacy and safety of is currently being assessed in the open-label extension of this trial."

Several authors disclosed financial ties to pharmaceutical companies, including GW Pharmaceuticals, which funded the study.

Explore further: Cannabis-based medicine may cut seizures in half for those with tough-to-treat epilepsy

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Cannabis-based medicine may cut seizures in half for those with tough-to-treat epilepsy

April 18, 2017
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy, according to new information released today from a large scale controlled clinical study ...

Cannabis derivative cannabidiol reduces seizures in severe epilepsy disorder

May 24, 2017
After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency by 39 percent for patients with Dravet syndrome - a rare, severe form of epilepsy - in the first large-scale ...

Review: cannabidiol may be beneficial for oral mucositis

February 16, 2017
(HealthDay)—Cannabidiol could be beneficial for the treatment of oral mucositis, although data on its use in dentistry are scarce, according to a review published online Feb. 12 in the Journal of Clinical Pharmacy and Therapeutics.

Clinical trials treat epilepsy patients in WNY with medical marijuana

January 22, 2016
For patients with severe forms of epilepsy that don't respond to other medications, hopes are high for marijuana as a treatment. But clinical data showing how well the drug works—and how safe it is—are sparse, experts ...

Cannabidiol benefits and mechanisms shown in mouse study of Dravet syndrome

October 10, 2017
Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder.

Medical marijuana liquid extract may bring hope for children with severe epilepsy

April 13, 2015
A medicinal liquid form of marijuana may show promise as a treatment for children with severe epilepsy that is not responding to other treatments, according to a study released today that will be presented at the American ...

Recommended for you

Green leafy vegetables may prevent liver steatosis

December 17, 2018
A larger portion of green leafy vegetables in the diet may reduce the risk of developing liver steatosis, or fatty liver. In a study published in PNAS researchers from Karolinska Institutet in Sweden show how a larger intake ...

Discovery of novel mechanisms that cause migraines

December 17, 2018
Researchers at CNRS, Université Côte d'Azur and Inserm have demonstrated a new mechanism related to the onset of migraine. They found how a mutation that causes dysfunction in a protein which inhibits neuronal electrical ...

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.